BRIACELL THERAPEUTICS CORP (BCT.CA) Stock Price, Forecast & Analysis
TSX:BCT • CA1079303071
BCT.CA Key Statistics, Chart & Performance
The current stock price of BCT.CA is 5.21 CAD. In the past month the price decreased by -11.09%. In the past year, price decreased by -99%.
BCT.CA Technical Analysis
BCT.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BCT.CA. No worries on liquidiy or solvency for BCT.CA as it has an excellent financial health rating, but there are worries on the profitability.
BCT.CA Financial Highlights
Over the last trailing twelve months BCT.CA reported a non-GAAP Earnings per Share(EPS) of -175.29. The EPS decreased by -184.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -219.56% | ||
| ROE | -287.71% | ||
| Debt/Equity | 0 |
BCT.CA Forecast & Estimates
BCT.CA Ownership
BCT.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 583.286M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 397.882M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 150.469M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 79.24M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.18 | 52.478M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.94 | 33.252M | ||
| RVX | RESVERLOGIX CORP | N/A | 33.069M | ||
| HEM | HEMOSTEMIX INC | N/A | 17.573M | ||
| MPH | MEDICURE INC | N/A | 11.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About BCT.CA
Company Profile
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Company Info
BRIACELL THERAPEUTICS CORP
Suite 300 - Bellevue Centre, 235 -15th Street
West Vancouver BRITISH COLUMBIA V7T 2X1 CA
CEO: William Williams
Employees: 16
Phone: 16049211810
BRIACELL THERAPEUTICS CORP / BCT.CA FAQ
What does BCT do?
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Can you provide the latest stock price for BRIACELL THERAPEUTICS CORP?
The current stock price of BCT.CA is 5.21 CAD. The price decreased by -4.23% in the last trading session.
Does BCT stock pay dividends?
BCT.CA does not pay a dividend.
How is the ChartMill rating for BRIACELL THERAPEUTICS CORP?
BCT.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for BRIACELL THERAPEUTICS CORP?
BRIACELL THERAPEUTICS CORP (BCT.CA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for BRIACELL THERAPEUTICS CORP?
BRIACELL THERAPEUTICS CORP (BCT.CA) has a market capitalization of 37.77M CAD. This makes BCT.CA a Nano Cap stock.
What is the ownership structure of BRIACELL THERAPEUTICS CORP (BCT.CA)?
You can find the ownership structure of BRIACELL THERAPEUTICS CORP (BCT.CA) on the Ownership tab.